Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long MRNA ETF

183.82
+39.8127.64%
Post-market: 176.67-7.1527-3.89%19:59 EDT
Volume:505.18K
Turnover:85.97M
Market Cap:55.15M
PE:- -
High:183.82
Open:145.71
Low:144.11
Close:144.01
52wk High:183.82
52wk Low:14.95
Shares:300.00K
Float Shares:300.00K
Volume Ratio:2.12
T/O Rate:168.39%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

BofA Securities Adjusts Price Target on Moderna to $200 From $170, Maintains Neutral Rating

MT Newswires Live
·
Oct 09

Moderna Inc Stock (MRNA) Moved Up by 7.63% on Oct 9: A Full Analysis

TradingKey
·
Oct 09

Teva announces FDA approval for Weltruza

TIPRANKS
·
Oct 09

Learn Why The Bull Case For Moderna Stock Could Change Following COO Appointment

Simply Wall St.
·
Oct 09

Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine

Reuters
·
Oct 09

RBC Capital Remains a Hold on Moderna (MRNA)

TIPRANKS
·
Oct 09

Cboe data shows mixed options sentiment in Moderna with shares down 0.56%

TIPRANKS
·
Oct 08

South Korea's Biopharmaceutical Exports Hit Record $6.6 Billion in First Nine Months

Deep News
·
Oct 08

Trading DAY-Stocks, Bonds in Delicate Dance

Reuters
·
Oct 08

Moderna Inc. Stock Rises 4.8%, Outperforms Peers

Dow Jones
·
Oct 08

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
Oct 08

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Oct 08

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 08

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07

Moderna Price Target Raised to $95.00/Share from $89.00 by Morgan Stanley

Dow Jones
·
Oct 07

Morgan Stanley Adjusts Price Target on Moderna to $95 From $89

MT Newswires Live
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07